Related to DSM to Manufacture Novacta’s C. Difficile Compound for Preclinical and Phase I Studies

• FDA Raps J&J's Knuckles over Clinical Trials of Ceftobiprole Antibiotic
  
• Australian Government Commissions DSM to Build Biomanufacturing Facility
  
• Trius Wins $29.5M Contract to Develop Antibiotics for Gram-Negative Pathogens
  
• Optimer Taps Biocon to Supply Commercial-Scale API for C. Difficile Treatment
  
• Tetraphase Pockets $45M to Progress Next-Generation Tetracyclines
  
• DSM and Crucell Turn Per.C6 R&D JV into Full-Fledged Biopharmaceutical Company
  
• CMOs DSM Biologics and ScinoPharm Separately Announce New Contracts
  
• Curetis Obtains €24.5M to Support Commercialization of Diagnostics for Infectious Diseases
  
• Sanofi Pays Rib-X $10M Up Front as Part of Antibiotics Collaboration
  
• Bayer Pays Trius $25M Up Front for License to Phase III-Stage Antibiotic
  
• CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand
  
• GSK Awarded $38.5M Contract to Develop Antibiotic for Biodefense and Drug-Resistant Infections
  
• TaiGen Acquires Global Rights to Warner Chilcott's Late-Stage Antibiotic
  
• Biovest, USAMRIID Sign CRADA to Evaluate Bioreactor Platform for Antiviral Vaccines and Drugs
  
• BIO Exclusive: Karen King Working to Keep DSM Moving Forward
  
• ZMC Nabs Chinese Rights to TaiGen’s Late-Stage Antibiotic for $8M
  
• BioFactura Scores Nearly $2M for Ebola Therapy and VRP Vaccine Production
  
• Flu Vaccine Manufacturing Gets Shot in Arm
  
• ABL Awarded up to $102M in NIH Contract
  
• Curetis Provides Pneumonia Testing for Antibiotic Study